The IL3 Knockout T-47D Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population derived from the T-47D human breast ductal carcinoma cell line, targeting the IL3 cytokine gene. This loss-of-function model enables study of IL3 signaling in a hormone receptor-positive breast cancer context and its potential non-hematopoietic functions. As a polyclonal population, it maintains genetic heterogeneity more representative of tumor diversity.
T-47D is a human breast ductal carcinoma cell line derived from pleural effusion of a metastatic breast cancer patient. It expresses estrogen, progesterone, and androgen receptors, serving as a well-established model for hormone-responsive breast cancer. Its steroid-responsive growth and stable receptor expression render it suitable for endocrine therapy studies, signaling assays, and drug screening.
IL3 encodes a hematopoietic cytokine regulating proliferation, differentiation, and survival of myeloid progenitors. It signals through the heterodimeric receptor IL3RA (CD123)/CSF2RB (CD131), activating JAK2 and phosphorylating STAT5A/B. Downstream pathways include RAS?CRAF1?CMAP2K1?CMAPK1/3 and PI3K?CAKT1?CmTOR, leading to transcription of targets like BCL2, CCND1, and MYC. Negative regulators include SOCS1, SOCS3, and PTPN11. Upstream, IL3 can be induced by IL?2, IL?18, and TCR/CD28 costimulation via NFAT, NF???B, and AP?1 transcription factors.
In T-47D breast carcinoma, IL3 knockout may disrupt autocrine/paracrine loops that influence tumor cell proliferation, survival, or crosstalk with the microenvironment. Although IL3 is traditionally hematopoietic, accumulating evidence implicates cytokine signaling in solid tumor progression and immune modulation. This polyclonal knockout model thus provides a unique experimental system to explore non-canonical IL3 functions in breast cancer, such as its impact on hormone receptor signaling dynamics or the secretion of factors that recruit stromal and immune cells.
Key applications include phospho-STAT5 analysis by flow cytometry or Western blot to monitor JAK/STAT pathway activation; RT?qPCR for IL3?responsive genes (BCL2, MYC, CCND1); functional proliferation assays; cytokine ELISA for IL3 secretion; flow?cytometric quantification of IL3RA surface expression; and co?culture setups with immune cells or stromal components to evaluate paracrine effects in the tumor microenvironment. In addition, the model supports preclinical validation of IL3R?directed therapies and combination studies in the context of hormone receptor?positive breast cancer. For further technical information or to tailor this product to specific experimental needs, please contact Ascent Research.
